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Introduction: The use of over-the-counter, prescription, and illicit drugs to
increase attention, concentration, or memory—often called (pharmacological)
neuroenhancement—shows a broad range of prevalence rates among students.
However, very little data is available on neuroenhancement among employed persons.
The aim of this study was to provide first data on substance use for neuroenhancement
among readers of the German “Handelsblatt” coming from the field of economics.
Methods: Readers of the online edition of the Handelsblatt, a leading print and
online medium for the field of economics, were invited to participate in a survey via
a link on the journal homepage to complete a web-based questionnaire. Within the
questionnaire, participants were asked for their gender, current age, current professional
status, hours of work per week, prevalence rates of substance use for the purpose of
neuroenhancement as well as for reasons of its use. Binary regression analyses with
stepwise forward selection were used to predict the dependent variables “use of illicit
and prescription drugs for neuroenhancement” (yes/no), “use of over-the-counter drugs
for neuroenhancement” (yes/no), and “use of any drug for neuroenhancement” (yes/no).
Results: A total of 1021 participants completed the anonymous survey. Lifetime
prevalence for the use of any drug for neuroenhancement was 88.0% and for the use
of illicit and prescription drugs for neuroenhancement 19.0%. Reasons and situations
that predicted neuroenhancement with illicit and prescription drugs were “curiosity,”
“to enhance mood,” ”for a confident appearance,” “stress/pressure to perform,” and
“deadline pressure.”
Discussion: The study shows that neuroenhancement with drugs is a widespread
and frequent phenomenon among people belonging to the professional field of
economics. Given in the literature that the use of drugs, especially prescription, and
illicit drugs, may be associated with side effects, the high epidemic of drug use for
neuroenhancement also shown in the present paper underlines the new public health
concern of neuroenhancement.
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INTRODUCTION
A 2008 publication of survey results about the use of
cognition-enhancing drugs among the readers of Nature
introduced a phenomenon called neuroenhancement
to the scientific world (Maher, 2008). Pharmacological
neuroenhancement is frequently defined as the use of any
drug to enhance vigilance, attention, concentration, memory,
mood, self-confidence, or self-expression without medical need
(Greely et al., 2008; Franke et al., 2014). Different terms have
been used such as “pharmaceutical/ pharmacological cognitive
enhancement,” “mood enhancement,” “academic performance
enhancement,” “academic doping,” “cosmetic neurology” etc. to
describe the above mentioned aim emphasizing the different
cognitive and/or non-cognitive domains and contexts of the use
(Chatterjee, 2004; Lucke et al., 2011; Partridge et al., 2011; Fond
et al., 2015; Franke et al., 2015b; Sahakian and Morein-Zamir,
2015).
The Nature poll assessed the use of Ritalin R©
(methylphenidate, MPH), Provigil R© (modafinil), and beta
blockers for neuroenhancement and found that one fifth of
the 1400 participants had used at least one of these drugs to
improve their focus, concentration or memory without medical
need. The most popular of the assessed drugs was Ritalin R© and
the most frequent reason for taking the drugs was to improve
concentration (Maher, 2008). However, the online poll was then
criticized by some authors in the Nature blog e.g., regarding the
methodology (e.g., participation bias).
An elaborative systematic review byWilens and colleagues had
already shown a past-year prevalence of 5-35% for the general
misuse of stimulants among college students (Wilens et al.,
2008). Meanwhile, numerous studies from different countries
have examined neuroenhancement among students and shown a
broad range of prevalence rates for neuroenhancement (between
1 and 20%), depending on the drugs assessed and the survey
methods used (McCabe et al., 2005; Boyd et al., 2006; Teter
et al., 2006; Franke et al., 2011a; Dietz et al., 2013a; Maier et al.,
2013; Webb et al., 2013). The most recent survey among students
“shows that prescription drugs, illicit drugs, and lifestyle drugs
are, respectively, used by 1.7, 1.3, and 45.6% of the sample”
(Schelle et al., 2015).
Surveys about the use of drugs for neuroenhancement in the
workplace are very rare. A recent survey among surgeons by
Franke and colleagues found a lifetime prevalence rate of 9%
for the use of prescription and illicit drugs, 13% for caffeine
tablets, and 24% for caffeinated drinks (which describes the
mainly German term “Energy drinks” included in the upper most
cases caffeine and taurine, excluding cola drinks; Franke et al.,
2013, 2015a). Using a technique for increased confidentiality
during the assessment (randomized response technique, RRT
Campbell, 1987; Moshagen et al., 2010), the group found a
lifetime prevalence rate for prescription and illicit drugs of 20%
(Franke et al., 2013). A survey by the German DAK found a
lifetime prevalence rate of 3.3% for “neuroenhancement” and
4.7% for “neuroenhancement to increase mood or to reduce
anxiety and nervousness” [Deutsche Angestelltenkrankenkasse
(DAK), 2015]. The KOLIBRI study found a last-year prevalence
of 1.5% for all prescription drugs (beta-blockers, stimulants,
MPH, antidementia drugs, antidepressants, and modafinil) and
1.0% of which was attributed to antidepressants [Robert-Koch-
Institut (RKI), 2011]. The most recent survey concerning
neuroenhancement in the workplace using an anonymizing
technique revealed a 12-month prevalence rate of 15.4% for
the use of prescription drugs among 1186 employed persons
(mostly teachers) in Jordan (Wolff et al., 2015). Furthermore, a
survey study by Franke and colleagues in 3300 surgeons showed
that reducing fatigue, working the night shift and excessive
work hours were frequent reasons for using PN substances.
This seems to show that coping with unfavorable working
conditions such as “stress” are important reasons for using
PN drugs (Franke et al., 2013, 2015a). Among students, stress
periods in the scope of preparation for exams are associated
with the use of PN drugs Burgard et al., 2013). However, among
teachers, the willingness of using PN drugs was shown to be low
(Sattler et al., 2013; Wiegel et al., 2015). The recent DAK study
among 5000 employees showed lifetime prevalence rates of 3.3%
for “neuroenhancement” and 4.7% for “neuroenhancement to
increase mood or to reduce anxiety and nervousness” [Deutsche
Angestelltenkrankenkasse (DAK), 2015].
Numerous studies with divergent study designs have
been performed with the group of drugs considered to be
neuroenhancers (Mehlman, 2004; De Jongh et al., 2008) to
assess the efficacy of the candidate drugs (Solomon et al.,
2002; Wesensten et al., 2002; Yesavage et al., 2002; Breitenstein
et al., 2004; Killgore et al., 2008, 2009). Overall, the group of
stimulants—methylxanthines, e.g., caffeine, and amphetamines,
e.g., MPH—seems to have broad pro-cognitive effects on simple
cognitive domains that can be affected in fatigued persons.
Furthermore, some studies indicate pro-cognitive effects on
certain higher cognitive domains, such as particular memory
domains. In addition, euphoric effects (in the scope of mood
neuroenhancement) of amphetamines have to be considered.
(Repantis et al., 2010a,b; Kelley et al., 2012; Franke et al., 2014).
The present web-based study design was inspired by the
above mentioned Nature poll with the aim to raise data from
persons who work in the field of economics or economic-related
studies. Therefore, the study assessed for the first time the use of
potential neuroenhancers based on an online poll posted on the
homepage of the “Handelsblatt” in order to capture data of their
readers.
We hypothesized that the prevalence rates of drug use
for neuroenhancement within the field of economics as well
as associated factors would be similar to previous studies in
students, physicians and scientists.
MATERIALS AND METHODS
The present survey was designed on the basis of the Nature poll
by Brendan Maher (Maher, 2008). We chose to advertise the
survey in the German “Handelsblatt,” a print and online medium
for people working in the field of economics. The Handelsblatt,
which until 2005 was part of the company that publishes the
Wall Street Journal in the US, is the leading economics journal
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in German-speaking countries; its print run in 2014 was 120,000
and in Germany it is the most cited print medium for economics
(Handelsblatt). Readers of the online edition of the Handelsblatt
were invited to participate in the present survey via a link on the
homepage of the journal (www.Handelsblatt.com)1.
Data Acquisition
To ensure a high degree of privacy and anonymity, the
survey was designed as an online poll with eight closed
questions about participants’ characteristics and their patterns
of drug use for neuroenhancement. The survey was open for
participation during the last 2 weeks of December 2014. Before
starting the survey, readers read a short introductory paragraph
that introduced them to the topic of neuroenhancement and
explained the survey. Then, after answering questions about their
gender, current age, current professional status, and hours of
work per week, participants were asked if they would at all
consider using (a) legal over-the-counter drugs (OTC drugs) (b)
prescription drugs, or (c) illicit drugs for neuroenhancement
or (d) no drugs for enhancement at all. Directly afterwards,
participants were asked to indicate any substances they had
already used for neuroenhancement by completing a table that
listed OTC drugs and prescription and illicit drugs as well as
drinks known to be frequently used for neuroenhancement by
students (Mehlman, 2004; De Jongh et al., 2008; Franke et al.,
2011b, 2014; Dietz et al., 2013b; Schelle et al., 2015) and surgeons
(Franke et al., 2013, 2015a): coffee, energy/caffeinated drinks,
caffeine tablets, cola drinks, Ginkgo biloba, Ritalin R©, Adderall R©,
modafinil, ecstasy, ephedrine, cocaine, crystal meth, illicit
amphetamines, and antidepressants. Subsequently, participants
were asked which of the following situations and reasons
were associated with their use of the aforementioned drug or
drugs for neuroenhancement (multiple responses were possible):
(a) curiosity, (b) stress/pressure to perform, (c) tiredness,
(d) to enhance mood, (e) for a confident appearance, (f)
deadline pressure, (g) other; these categories were identified in
previous studies in students as reasons and situations commonly
associated with the use of drugs for neuroenhancement.
In order to exclude from further analysis participants who
used certain prescription drugs to treat a disease, participants
were asked if they suffered from attention-deficit-hyperactivity
disorder (ADHD) or depression. Participants who stated to “have
been diagnosed” with ADHD or depression were excluded.
Data Analysis
Data were collected in a database connected directly to the survey
questionnaire. Statistical analyses were performed with SPSS for
Windows, version 22.0. Binary regression analysis with stepwise
forward selection was used to predict the dependent variables
“use of illicit and prescription drugs for neuroenhancement”
(yes/no), “use of OTC drugs for neuroenhancement” (yes/no),
and “use of any drug for neuroenhancement” (yes/no).
Continuous variables (age, hours of work per week) were
dichotomized by mean. Results are given as means and standard
1According to a personal communication from the Handelsblatt and
www.Handelsblatt.com (accessed in april 2015) and www.ivw.eu (accessed
in april 2015).
deviations (SD), prevalence rates (%), or odds ratios (OR) with
Clopper-Pearson confidence intervals (95% CI) and p-values.
Ethics Statement
The study was performed according to the Declaration of
Helsinki. Participants gave informed consent by clicking on a
button after reading the short introductory paragraph and by
pressing the button “done” at the end of the survey. The study
was approved by the responsible ethics committee (Greifswald;
approval no. BB 095/14).
RESULTS
In total, 1021 readers of the journal Handelsblatt participated
in the survey. Among the participants, 6.6% (n = 67) reported
to have been diagnosed with ADHD or depression and had to
be excluded from further analysis. Therefore, the data of 954
participants were analyzed. Most of the participants were male
(82.7%), with a mean age of 36.3 years. Approximately one-
third of the participants rated themselves as belonging to “middle
management” (32.4%). Participants worked aF mean of 48.7
h per week. Table 1 gives a detailed description of participant
characteristics.
Regarding the question of whether the participants would
consider using any substance for neuroenhancement, 40.0% (n
= 372) answered “yes, an OTC substance,” 12.6% (n = 117)
answered “yes, a prescription drug” and 8.3% (n = 77) answered
“yes, an illicit drug.”
Among all participants, 88.0% (n = 831) had used one of
the listed substances (see Materials and Methods Section) for
neuroenhancement purposes at least once in their life (lifetime
prevalence): lifetime prevalence was 87.5% (n = 824) for the use
of any OTC drug for neuroenhancement and 19.0% (n= 171) for
the use of any prescription or illicit drug for neuroenhancement.
Among the group of OTC drugs and drinks the most commonly
used substance was coffee (lifetime prevalence: 77.1%, n = 723),
TABLE 1 | Basic characteristics of the survey participants.
Characteristic Frequency or range, mean and standard
deviation of characteristic among
participants (N = 954)
Gender 82.7% male (n = 767)
17.3% female (n = 160)
Age, y (mean, SD) 17–71 (36.3, 11.2)
CURRENT PROFESSION
“Simple” employee 28.8% (n = 270)
Middle management 32.4% (n = 304)
Top management 9.6% (n = 90)
Freelancer 12.5% (n = 117)
Public official 1.5% (n = 14)
Student studying economics 15.0% (n = 141)
Not working 0.3% (n = 3)
Hours of work per week, h
(mean, SD)
4–100 (48.7, 11.1)
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followed by cola drinks (Coca-Cola R©, etc.; lifetime prevalence:
56.6%, n = 521; see Table 2). The most frequently used
drugs among the group of prescription and illicit drugs were
antidepressants, with a lifetime prevalence of 7.2% (n= 65) and a
period prevalence rate in the last month of 2.0% (n= 18); during
the last month only cocaine was used more frequently (2.3%, n
= 20; Table 2). For more detailed information about prevalence
rates, see Table 2.
The most frequently mentioned situations or reasons
associated with using any drug for neuroenhancement including
OTC and prescription and illicit drugs were “tiredness” (79.4%,
n = 533), “stress/pressure to perform” (41.7%, n = 280), and
“to enhance mood” (22.2%, n = 149). The rates for “deadline
pressure,” “curiosity,” “for a confident appearance,” and “others”
were 17.3% (n = 116), 12.2% (n = 82), 11.8% (n = 79), and
11.5% (n = 77), respectively; Table 3 gives further details about
situations or reasons associated with the use of OTC drugs and
prescription and illicit drugs.
Binary logistic regression revealed five independent variables
that predict the use of illicit and prescription drugs for
neuroenhancement: “curiosity,” “stress/pressure to perform,” “to
enhance mood,” “for a confident appearance,” and “deadline
pressure” (see Table 4). The dichotomized independent variables
“age” and “hours of work per week” as well as each of the items
“current profession,” “using OTC drugs for neuroenhancement,”
“gender,” and “tiredness” did not significantly predict the use of
illicit and prescription drugs for neuroenhancement. Only two
independent predictor variables, “tiredness” and “stress/ pressure
to perform,” were found for OTCdrug use for neuroenhancement
and for the use of any substance for neuroenhancement
(including OTC, illicit and prescription drugs), respectively (see
Table 4).
The areas under the receiving operation curve (ROC)
of the overall regression models were 77.2% for “use
of illicit and prescription drugs for neuroenhancement,”
85.5% for “use of OTC drugs for neuroenhancement,” and
TABLE 2 | Prevalence rates for use of substances for neuroenhancement among survey participants (N = 954).
Use of any surveyed substance Never used Used
Total responses Within the last month Within the last 12 months More than 12 months ago
OTC DRUGS/DRINKS
Coffee 22.9% 77.1% 43.5% 7.6% 26.0%
(n = 215) (n = 723) (n = 408) (n = 71) (n = 244)
Energy/caffeinated drinks 53.3% 46.7% 21.0% 13.6% 12.0%
(n = 489) (n = 428) (n = 193) (n = 125) (n = 110)
Caffeine tablets 74.9% 25.1% 5.8% 6.3% 13.0%
(n = 669) (n = 224) (n = 52) (n = 56) (n = 116)
Cola drinks (e.g., Coca-Cola, etc.) 43.4% 56.6% 31.2% 11.5% 13.9%
(n = 399) (n = 521) (n = 287) (n = 106) (n = 128)
Ginkgo biloba 89.4% 10.6% 2.7% 3.7% 4.1%
(n = 788) (n = 93) (n = 24) (n = 33) (n = 36)
PRESCRIPTION AND ILLICIT DRUGS
Ritalin 94.9% 5.1% 1.5% 1.9% 1.7%
(n = 852) (n = 45) (n = 13) (n = 17) (n = 15)
Adderall 96.7% 3.3% 0.8% 0.8% 1.7%
(n = 853) (n = 29) (n = 7) (n = 7) (n = 15)
Modafinil 97.7% 2.3% 0.9% 0.5% 0.9%
(n = 857) (n = 20) (n = 8) (n = 4) (n = 8)
Ecstasy 95.6% 4.4% 1.6% 0.9% 1.9%
(n = 843) (n = 39) (n = 14) (n = 8) (n = 17)
Ephedrine 94.7% 5.3% 1.6% 1.4% 2.3%
(n = 829) (n = 46) (n = 14) (n = 12) (n = 20)
Cocaine 93.5% 6.5% 2.3% 1.3% 3.0%
(n = 820) (n = 57) (n = 20) (n = 11) (n = 26)
Crystal meth 98.2% 1.8% 0.6% 0.5% 0.8%
(n = 857) (n = 16) (n = 5) (n = 4) (n = 7)
Illicit AMPH 93.0% 7.0% 1.9% 1.9% 3.2%
(n = 826) (n = 62) (n = 17) (n = 17) (n = 28)
Antidepressants 92.8% 7.2% 2.0% 2.5% 2.7%
(n = 839) (n = 65) (n = 18) (n = 23) (n = 24)
AMPH, amphetamines; “ever,” within the last month + within the last 12 months + more than 12 months ago; OTC drugs, over-the-counter drugs.
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TABLE 3 | Reasons and situations associated with the use of drugs for
neuroenhancement.
OTC drugs
(N = 669)
Prescription
and illicit drugs
(N = 155)
OTC drugs +
prescription and
illicit drugs (N = 671)
Curiosity 12.1% 31.0% 12.2%
(n = 81) (n = 48) (n = 82)
Stress, pressure to
perform
41.7% 60.6% 41.7%
(n = 279) (n = 94) (n = 280)
Tiredness 79.4% 72.3% 79.4%
(n = 531) (n = 112) (n = 533)
To enhance mood 22.1% 45.8% 22.2%
(n = 148) (n = 71) (n = 149)
For a confident
appearance
11.7% 29.0% 11.8%
(n = 78) (n = 45) (n = 79)
Deadline pressure 17.2% 28.4% 17.3%
(n = 115) (n = 44) (n = 116)
Others 11.5% 16.8% 11.5%
(n = 77) (n = 26) (n = 77)
OTC drugs, over-the-counter drugs.
88.1% for “use of any substance for neuroenhancement,”
respectively.
DISCUSSION
This study used an anonymous web-based questionnaire
to investigate for the first time the use of drugs for
neuroenhancement among the “Handelsblatt” readership
working or at least studying in the field of economics. The study
shows that the prevalence rates of neuroenhancement in the
surveyed participants within the field of economics are similar to
those in other highly demanding fields. Although, the associated
reasons and situations are somewhat similar, non-cognitive
reasons for neuroenhancement are much more important in our
participants than among the previously studied groups (students,
surgeons).
Among the large number of papers on neuroenhancement,
one of the most extensive studies (in 8000 students) found
lifetime prevalence rates of 5% for prescription drugs and 5%
for so-called “soft enhancement” (use of vitamins, homeopathic
drugs, “herbal” substances, caffeine, etc.), i.e., significantly lower
rates than that in our study (40.0%; Middendorff et al., 2012).
There is a paucity of data about neuroenhancement among the
general population and employed persons in particular. For their
2015 health report, a German health insurance company (DAK)
re-assessed a representative panel of 5000 participants aged
between 20 and 50 years [Deutsche Angestelltenkrankenkasse
(DAK), 2015]. The online study had a response rate of 49.1% and
found lifetime prevalence rates of 3.3% for “neuroenhancement”
and 4.7% for “neuroenhancement to increase mood or to reduce
anxiety and nervousness” [Deutsche Angestelltenkrankenkasse
(DAK), 2015]. Cognitive neuroenhancement was more frequent
among men, and mood neuroenhancement, as well as reduction
of anxiety and nervousness, more frequent among women
TABLE 4 | Predicting factors for the use of substances for
neuroenhancement.
Predictor OR (95% CI)
USE OF ILLICIT AND PRESCRIPTION DRUGS FOR
EUROENHANCEMENT
Curiosity 4.79*** (2.75–8.33)
To enhance mood 2.72*** (1.68–4.42)
For a confident appearance 2.69** (1.47–4.91)
Stress/ pressure to perform 1.83* (1.15–2.91)
Deadline pressure 1.79* (1.03–3.11)
USE OF OTC DRUGS FOR NEUROENHANCEMENT
Tiredness 22.44*** (4.68–107.64)
Stress/pressure to perform 10.15*** (1.24–83.01)
USE OF ANY SUBSTANCE FOR NEUROENHANCEMENT
Tiredness 45.24*** (5.46–374.77)
Stress/pressure to perform 9.59*** (1.13–81.12)
Odds ratios for the dependent variables “use of illicit and prescription drugs for
neuroenhancement,” “use of OTC-drugs for neuroenhancement,” and “use of any
substance for neuroenhancement” and each predictor variable (stepwise, forward
regression). Levels of significance: p < 0.05*; p < 0.01**; p < 0.001***; (CI, confidence
interval; OR, odds ratio); OTC drugs, over-the-counter drugs.
[Deutsche Angestelltenkrankenkasse (DAK), 2015]. This finding
is in contrast to our study results. We found significantly higher
prevalence rates and no differences between men and women
regarding special patterns of substance use which may be due to
the inequal preponderance in our study in contrast to the DAK
study. However, in line with the DAK study we found higher
prevalence rates for mood neuroenhancement than for cognitive
neuroenhancement, which we consider to be one of the most
important findings of our study.
The Kolibri study evaluated 6000 participants from the
general public and found a last-year prevalence of 1.5%
for all prescription drugs (beta-blockers, stimulants, MPH,
antidementia drugs, antidepressants and modafinil), 1.0% of
which was attributed to antidepressants [Robert-Koch-Institut
(RKI), 2011]. The relatively high prevalence rates for the use of
potential mood-enhancing substances concur with our findings.
One German web-based study used vignettes to examine the
prevalence rate of neuroenhancement among university teachers
and their willingness to use drugs for neuroenhancement and
found both to be low (Sattler et al., 2013; Wiegel et al., 2015).
However, teachers are not comparable with the participants
surveyed in this study.
The Nature poll mentioned above found a lifetime prevalence
rate of 20% for the use of beta-blockers, methylphenidate (MPH;
Ritalin R©), and modafinil (Maher, 2008) which is nearly the same
as that found among the participants of the present survey
(19.0% lifetime prevalence rate for prescription and illicit drug
use). Ritalin R© was the most commonly used drug in the Nature
poll, and in our study lifetime prevalence rates were highest
for illicit amphetamines. Considering that MPH belongs to
the group of amphetamines and Ritalin R© was the third most
frequently used prescription/illicit drug in our survey, the results
are again comparable. Beyond the question of the frequency of
use for neuroenhancement, Maher found that the most popular
Frontiers in Psychology | www.frontiersin.org 5 April 2016 | Volume 7 | Article 520
Dietz et al. Cognitive Enhancement in White-Collar Workers
reasons for the use of the three assessed drugs were to improve
concentration, improve focus for a specific task, and counteract
jetlag (Maher, 2008). Interestingly, these reasons do not overlap
with those found in our study, which identified curiosity, mood
neuroenhancment, and confident appearance as the three most
important reasons for neuroenhancement.
Franke et al. studied 3300 surgeons and found a lifetime
prevalence rate for the use of prescription and illicit stimulants
of 8.9% when participants completed a direct questioning survey
(paper-and-pencil questionnaire) and 19.9%when the specialized
anonymizing survey technique RRT was applied (Franke et al.,
2013, 2015a). Furthermore, lifetime, past-year, past-month, and
past-week prevalence rates for coffee were 66.8, 61.9, 56.9, and
50.5%, for caffeinated drinks 24.2, 15.4, 9.9, and 6.1%, and for
caffeine tablets 12.6, 5.9, 4.7, and 3.8%, respectively. Although,
prevalence rates for coffee were similar to those in the present
study, those for caffeinated/energy drinks and caffeine tablets
were significantly lower (Franke et al., 2015a). Prevalence rates
for (psycho-) stimulants were higher among surgeons than in our
study (Franke et al., 2013).
Among surgeons, reducing fatigue (54.3%), working the night
shift (32.2%), and overly long and excessive work hours (31.7%)
were the most frequent reasons for using caffeine (Franke
et al., 2013). This finding could only be partially confirmed in
the present study, which identified tiredness, stress/ pressure
to perform, and mood neuroenhancement as the three most
important reasons for using caffeine.
When Franke and colleagues compared the use of prescription
and illicit drugs by surgeons for cognitive neuroenhancement
with the use of antidepressants for mood neuroenhancement,
which was a separate category in the study, they found lifetime
prevalence rates of 8.9% for the former and only 2.4% for
the latter (Franke et al., 2013). Our study found much higher
prevalence rates for antidepressant use without medical need
(7.2%, n = 65), i.e., the rate was three-fold higher among the
present participants. The reason for this discrepancy is unclear.
Therefore, future studies should address in detail the reasons why
participants use drugs for the purpose of neuroenhancement and
for mood enhancement.
The question of anonymity and privacy when using a survey
about potentially stigmatizing issues is complex. Empirical
social science has shown a tendency for people to answer
with socially desirable answers when asked about sensitive or
stigmatizing issues (e.g., own thievery; Schnell et al., 1992).
This aspect is important when asking participants about
their use of neuroenhancement drugs which, at least in the
case of misusing prescription drugs and using illicit drugs,
is potentially punishable. Therefore, other studies using the
RRT—which is only one among a variety of techniques for
the assessment of socially undesirable behavior (Campbell,
1987; Moshagen et al., 2010; Wolff et al., 2015)—to assess
the use of antidepressants among surgeons, found prevalence
rates of 19% for cognitive neuroenhancement and 15%
for mood neuroenhancement. Prevalence rates for cognitive
neuroenhancement are comparable to our results; however,
prevalence rates for mood neuroenhancement are considerably
higher. Comparable prevalence rates for neuroenhancement may
imply that an online poll gives a subjective feeling of anonymity
and privacy similar to the RRT, perhaps because (more or less)
nobody can trace answers back to the participants.
Taken together, the high discrepancy between the direct
questioning and RRT results for antidepressants and the high
prevalence rates for the use of antidepressants found in the
present study could mean that mood neuroenhancement and
not cognitive neuroenhancement is the “core enhancement”
phenomenon. Because stimulants also have euphoric effects,
they are perhaps being used for both purposes. An as yet
underestimated reason could be to feel more self-confident
and to enhance mood. Even though this assumption is highly
speculative, it is supported by the present study and may
therefore warrant further investigation.
In addition to the aspects mentioned above, some factors
should be addressed that limit the explanatory power of this
study. As with every survey study, one can discuss the suitability
of the content and length of the questionnaire and the likelihood
of complete participation. Our questionnaire, inspired by the
online Nature poll (Maher, 2008) was designed to increase the
likelihood of participation and the completeness of participants’
responses at the expense of losing a large amount of information
because of its brevity. Therefore, the authors designed the
questionnaire on the basis of the available neuroenhancement
literature to be brief but nevertheless informative. A web-
based survey has an inherent risk of participation bias because
one cannot control for participants’ experiences, opinions,
personal characteristics, and subjective aims when answering the
questions. Nevertheless, we considered such a survey the best way
to collect “real life” data and gain insight into the fast-paced field
of economics.
The main strength of this study, its high degree of anonymity
and privacy, is also the cause of one of its most limiting factors,
the participation bias. Because the present study was voluntarily
conducted as an online poll—to guarantee the highest degree
of anonymity and privacy—in the Handelsblatt, readers of the
online version of this specific journal were able to participate.
However, because of the possibility to distribute links via social
media networks, it cannot be guaranteed that only readers of
the Handelsblatt participated. This may explain the fact, that the
group of participants is more or less heterogeneous. Means to
reduce participation bias and to control for participation (e.g., via
participation codes, etc.) leads to reduced anonymity and privacy
and were not considered by the authors in order to receive honest
answers. This major limitation was of similar concern in the
Nature poll by Brendan Maher.
Beyond that, the online version is widely read and only
∼1000 individuals participated, which may not be representative
of only those working in the field of economics. Furthermore,
we have no information about possible specific characteristics
of the individuals who did not participate. Therefore, we do
not know whether those individuals would have increased or
decreased the prevalence rate for neuroenhancement or shown
additional predictors. Online surveys cannot control for such a
disproportion and response bias.
In sum, the study results presented here show that drug
use to increase cognition, enhance mood, improve confidence,
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or cope with stress and pressure seems to be a widespread
phenomenon within the field of economics. Taken together, the
results of this and previous studies indicate that the findings
of studies in high school, college, and university students
may also be valid in employed persons. Findings in employed
persons such as surgeons, individuals working in the professional
field of economics, and natural scientists demonstrate that
neuroenhancement has become a widespread phenomenon. Both
are associated with health concerns, because any (mis-) use
of drugs may have adverse effects on mental and physical
health. For example, any stimulant is associated with the risk of
cardiovascular events, hypertonia, tachycardia, and even sudden
cardiac death (e.g., Kumar, 2008; Ali et al., 2015; Vetter et al.,
2015). Such events may be more frequent when drugs are
misused without a physicians’ prescription or are mixed with
other drugs. Additionally, drug misuse can lead to addiction and
be a gateway for the use of other—more harmful or illicit—
drugs (Kandel, 2002; Dietz et al., 2013b, 2016). Taking these
negative aspects together and considering the high prevalence
rates of drug use for neuroenhancement, we think that the
creation of prevention programs and related educational material
is of great public health relevance. A large journal with an
online version like the Handelsblatt, which is read by a potential
at-risk population, could be used to spread information and
material about such programs. Additionally, the predictors
for drug use for neuroenhancement identified in the present
study may help to create well-directed prevention programs
and education material tailored more closely to individual
needs. As the metric scaled variables in the present study were
dichotomized for analyses, one implication for future studies
would be to provide more individual profiles of drug users,
addressing more specific demographic characteristics, rather
than the dichotomized method used in the current study.
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